Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2024-02-15T05:11:28Z | - |
dc.date.available | 2024-02-15T05:11:28Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2234-943X | * |
dc.identifier.other | OAK-34363 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267682 | - |
dc.description.abstract | IntroductionPegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as a primary prophylaxis of febrile neutropenia and infection among patients with relapsed refractory multiple myeloma (RRMM) treated with pomalidomide-based regimens.MethodsThirty-three patients with RRMM who received pomalidomide and dexamethasone (Pd) with or without cyclophosphamide (PCd) were enrolled in this study. Twenty-eight patients were treated with PCd and 5 patients were treated with Pd. All patients were given pegfilgrastim subcutaneously with a single administration performed on the first day of each cycle as primary prophylaxis until the fourth cycle.ResultsThe median age of the patients was 75 (range 56-85), and the median prior line of therapy was 2 (range 2-6). Seventeen patients (51.5%) had any grade of neutropenia and 20 (60.6%) had any grade of thrombocytopenia before starting pomalidomide treatment. During the 4 cycles of treatment, grade 3 or more neutropenia occurred in 17 patients (51.5%), and 4 (12.1%) experienced grade 3 or more febrile neutropenia. Grade 3 or more infections occurred in 5 patients (15.2%). Interestingly, the patients with markedly increased ANC of more than 2 x 109/L compared to baseline ANC after 7 days of pegfilgrastim at 1st cycle of treatment showed a significantly lower incidence of grade 3-4 neutropenia. The most common adverse event of pegfilgrastim was fatigue, and all the adverse events caused by pegfilgrastim were grade 1 or 2. And there was no significant change in the immune cell population and cytokines during the administration of pegfilgrastim.DiscussionConsidering that this study included elderly patients with baseline neutropenia, pegylated G-CSF could be helpful to prevent severe neutropenia, febrile neutropenia, or infection in patients with RRMM. | * |
dc.language | English | * |
dc.publisher | FRONTIERS MEDIA SA | * |
dc.subject | pegfilgrastim | * |
dc.subject | prophylaxis | * |
dc.subject | febrile neutropenia | * |
dc.subject | multiple myeloma | * |
dc.subject | pomalidomide | * |
dc.title | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) | * |
dc.type | Article | * |
dc.relation.volume | 13 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | FRONTIERS IN ONCOLOGY | * |
dc.identifier.doi | 10.3389/fonc.2023.1209110 | * |
dc.identifier.wosid | WOS:001097619200001 | * |
dc.author.google | Song, Ga-Young | * |
dc.author.google | Lee, Je-Jung | * |
dc.author.google | Moon, Joon Ho | * |
dc.author.google | Kim, Dajung | * |
dc.author.google | Kim, Min Kyoung | * |
dc.author.google | Kim, Hyo Jung | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Lee, Won-Sik | * |
dc.author.google | Do, Young Rok | * |
dc.author.google | Lee, Jae Hoon | * |
dc.author.google | Jung, Sung-Hoon | * |
dc.author.google | Kim, Jin Seok | * |
dc.author.google | Korean Multiple Myeloma Working Party | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |